Darzalex is named as an intervention in 2 current clinical trials in our China, UK and USA registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is AstraZeneca (1). The most-studied condition is Relapsed Refractory Multiple Myeloma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657 · ClinicalTrials.gov ↗ · Relapsed Refractory Multiple Myeloma
|
Phase 3 | Recruiting | AstraZeneca | UK, USA, China |
|
A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
NCT06895512 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma
|
Phase 3 | Not yet open | Shanghai Henlius Biotech | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Shanghai Henlius Biotech | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China, UK and USA registers name Darzalex as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China, 1 with sites in UK and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AstraZeneca (1) and Shanghai Henlius Biotech (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Darzalex works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Darzalex works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Darzalex (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.